Literature DB >> 32154561

The Impact of Mild Autonomous Cortisol Secretion on Bone Turnover Markers.

Shobana Athimulam1, Danae Delivanis2, Melinda Thomas1, William F Young1, Sundeep Khosla1, Matthew T Drake1, Irina Bancos1.   

Abstract

CONTEXT: Several studies have reported increased risk of fragility fractures in patients with mild autonomous cortisol secretion (MACS), discordant to the degree of bone density deterioration.
OBJECTIVE: To evaluate the effect of MACS on bone metabolism in patients with adrenal adenomas.
DESIGN: Cross-sectional study with prospective enrollment, 2014-2019.
SETTING: Referral center. PATIENTS: 213 patients with adrenal adenomas: 22 Cushing syndrome (CS), 92 MACS and 99 nonfunctioning adrenal tumors (NFAT). MAIN OUTCOME MEASURES: Osteocalcin, procollagen I intact N-terminal (PINP), C-terminal telopeptide (CTX), sclerostin.
RESULTS: Patients with CS demonstrated lower markers of bone formation compared with patients with MACS and NFAT (CS vs MACS vs NFAT: mean osteocalcin 14.8 vs 20.1 vs 21.3 ng/mL [P < 0.0001]; mean PINP 34.8 vs 48.7 vs 48.5 µg/L [P = 0.003]). Severity of cortisol excess was inversely associated with sclerostin (CS vs MACS vs NFAT: mean sclerostin 419 vs 538 vs 624 ng/L, [P < 0.0001]). In a multivariable model of age, sex, body mass index, cortisol, and bone turnover markers, sclerostin was a significant predictor of low bone mass in patients with MACS (OR 0.63 [CI 95%, 0.40-0.98] for each 100 ng/L of sclerostin increase).After adrenalectomy, osteocalcin, CTX, and sclerostin increased by a mean difference of 6.3 ng/mL, 0.12 ng/mL, and 171 pg/mL (P = 0.02 for all), respectively.
CONCLUSIONS: Lower sclerostin level in patients with MACS reflects a reduction in osteocyte function or number associated with exposure to chronic cortisol excess. Increase in bone turnover markers after adrenalectomy suggests restoration of favorable bone metabolism. © Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Cushing syndrome; MACS; bone turnover markers; nonfunctioning adrenal tumors; osteopenia; osteoporosis; sclerostin

Mesh:

Substances:

Year:  2020        PMID: 32154561      PMCID: PMC7108681          DOI: 10.1210/clinem/dgaa120

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  31 in total

1.  Bone loss rate in adrenal incidentalomas: a longitudinal study.

Authors:  I Chiodini; M Torlontano; V Carnevale; G Guglielmi; M Cammisa; V Trischitta; A Scillitani
Journal:  J Clin Endocrinol Metab       Date:  2001-11       Impact factor: 5.958

2.  Factors predicting the duration of adrenal insufficiency in patients successfully treated for Cushing disease and nonmalignant primary adrenal Cushing syndrome.

Authors:  Alessandro Prete; Rosa Maria Paragliola; Filomena Bottiglieri; Carlo Antonio Rota; Alfredo Pontecorvi; Roberto Salvatori; Salvatore Maria Corsello
Journal:  Endocrine       Date:  2016-07-09       Impact factor: 3.633

3.  Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice.

Authors:  Wei Yao; Zhiqiang Cheng; Cheryl Busse; Aaron Pham; Mary C Nakamura; Nancy E Lane
Journal:  Arthritis Rheum       Date:  2008-06

4.  Altered bone mass and turnover in female patients with adrenal incidentaloma: the effect of subclinical hypercortisolism.

Authors:  M Torlontano; I Chiodini; M Pileri; G Guglielmi; M Cammisa; S Modoni; V Carnevale; V Trischitta; A Scillitani
Journal:  J Clin Endocrinol Metab       Date:  1999-07       Impact factor: 5.958

5.  Prevalence of adrenal incidentaloma in a contemporary computerized tomography series.

Authors:  S Bovio; A Cataldi; G Reimondo; P Sperone; S Novello; A Berruti; P Borasio; C Fava; L Dogliotti; G V Scagliotti; A Angeli; M Terzolo
Journal:  J Endocrinol Invest       Date:  2006-04       Impact factor: 4.256

6.  Risk of new vertebral fractures in patients with adrenal incidentaloma with and without subclinical hypercortisolism: a multicenter longitudinal study.

Authors:  Valentina Morelli; Cristina Eller-Vainicher; Antonio Stefano Salcuni; Francesca Coletti; Laura Iorio; Giovanna Muscogiuri; Silvia Della Casa; Maura Arosio; Bruno Ambrosi; Paolo Beck-Peccoz; Iacopo Chiodini
Journal:  J Bone Miner Res       Date:  2011-08       Impact factor: 6.741

7.  Bone turnover in patients with endogenous Cushing's syndrome before and after successful treatment.

Authors:  A Szappanos; J Toke; D Lippai; A Patócs; P Igaz; N Szücs; L Füto; E Gláz; K Rácz; M Tóth
Journal:  Osteoporos Int       Date:  2009-06-10       Impact factor: 4.507

8.  Eugonadal male patients with adrenal incidentalomas and subclinical hypercortisolism have increased rate of vertebral fractures.

Authors:  Iacopo Chiodini; Raffaella Viti; Francesca Coletti; Giuseppe Guglielmi; Claudia Battista; Federica Ermetici; Valentina Morelli; Antonio Salcuni; Vincenzo Carnevale; Filomena Urbano; Silvana Muscarella; Bruno Ambrosi; Maura Arosio; Paolo Beck-Peccoz; Alfredo Scillitani
Journal:  Clin Endocrinol (Oxf)       Date:  2008-06-10       Impact factor: 3.478

9.  Spinal volumetric bone mineral density and vertebral fractures in female patients with adrenal incidentalomas: the effects of subclinical hypercortisolism and gonadal status.

Authors:  Iacopo Chiodini; Giuseppe Guglielmi; Claudia Battista; Vincenzo Carnevale; Massimo Torlontano; Mario Cammisa; Vincenzo Trischitta; Alfredo Scillitani
Journal:  J Clin Endocrinol Metab       Date:  2004-05       Impact factor: 5.958

10.  Bone metabolism and mass in women with Cushing's syndrome and adrenal incidentaloma.

Authors:  Cristiano Maria Francucci; Paola Pantanetti; Gabriella Giuseppina Garrapa; Fernando Massi; Giorgio Arnaldi; Franco Mantero
Journal:  Clin Endocrinol (Oxf)       Date:  2002-11       Impact factor: 3.478

View more
  4 in total

Review 1.  Steroid profiling in the diagnosis of mild and overt Cushing's syndrome.

Authors:  Shobana Athimulam; Stefan Grebe; Irina Bancos
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2021-02-06       Impact factor: 4.690

2.  Risk of bone fractures after the diagnosis of adrenal adenomas: a population-based cohort study.

Authors:  Dingfeng Li; Ravinder Jeet Kaur; Catherine D Zhang; Andreas Ebbehoj; Sumitabh Singh; Elizabeth J Atkinson; Sara J Achenbach; Walter Rocca; Sundeep Khosla; Irina Bancos
Journal:  Eur J Endocrinol       Date:  2021-04       Impact factor: 6.558

3.  Effect of adrenocorticotropic hormone infusion on circulating sclerostin levels.

Authors:  Sarah Zaheer; Kayla Meyer; Rebecca Easly; Omar Bayomy; Janet Leung; Andrew W Koefoed; Mahyar Heydarpour; Roy Freeman; Gail K Adler
Journal:  Endocr Connect       Date:  2021-12-14       Impact factor: 3.335

4.  Sex Difference in the Association of Osteoporosis and Osteopenia Prevalence in Patients with Adrenal Adenoma and Different Degrees of Cortisol Excess.

Authors:  Shoichiro Izawa; Kazuhisa Matsumoto; Kazuhiko Matsuzawa; Takuyuki Katabami; Takanobu Yoshimoto; Michio Otsuki; Masakatsu Sone; Yoshiyu Takeda; Shintaro Okamura; Takamasa Ichijo; Mika Tsuiki; Tomoko Suzuki; Mitsuhide Naruse; Akiyo Tanabe
Journal:  Int J Endocrinol       Date:  2022-03-18       Impact factor: 3.257

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.